PCSK9 Inhibition to Reduce Cardiovascular Risk: Tempering Expectations
A short and readable commentary on monoclonal antibodies and dyslipidaemias, particularly on FOURIER, SPIRE and ODYSSEY trials
0
0 comments
A short and readable commentary on monoclonal antibodies and dyslipidaemias, particularly on FOURIER, SPIRE and ODYSSEY trials
New to CTSNet? Sign Up